Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine among Reproductive-aged Women in the U.S. South.
Lauren F CollinsAnandi N ShethTina TisdaleC Christina MehtaGaea DanielDaniel WestreichSeble KassayeElizabeth F TopperDeborah Konkle-ParkerAadia RanaMaria L AlcaideMorgan M PhilbinPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Among 103 reproductive-aged women with HIV in the U.S. South surveyed post-approval of long-acting injectable (LAI) cabotegravir/rilpivirine, nearly two-thirds reported willingness to try LAI antiretroviral therapy (ART). Most expressed preference for LAI over daily oral ART and had minimal concerns over potential LAI-ART use impacting reproductive health.